Timber Pharmaceuticals Inc

ASE:TMBR   3:51:17 PM EDT
1.11
+0.05 (+4.72%)
Products, Regulatory

Timber Pharmaceuticals Announces 50% Enrollment In Phase 2B Control Study In Congenital Ichthyosis

Published: 03/15/2021 13:18 GMT
Timber Pharmaceuticals Inc (TMBR) - Timber Pharmaceuticals Announces 50% Enrollment in Phase 2b Control Study in Congenital Ichthyosis.
Timber Pharmaceuticals Inc - Study is Evaluating Tmb-001 (topical Isotretinoin) in Subtypes of Rare Genetic Keratinization Disorder.
Timber Pharmaceuticals Inc - Awarded Final Tranche of $1.5 Million FDA Orphan Products Clinical Trials Grant.
Timber Pharmaceuticals Inc - Phase 2b Control Study is Targeting Enrollment of 45 Patients Aged Nine Years Old and Older.